Pharmaceutical - Novartis

Filter

Current filters:

Novartis

Popular Filters

1 to 25 of 357 results

FTC puts conditions on GSK/Novartis consumer JV

27-11-2014

The US Federal Trade Commission has voted to approve UK pharma giant GlaxoSmithKline’s proposed acquisition…

Dr Reddy's LaboratoriesGlaxoSmithKlineHabitrolMergers & AcquisitionsNicodermNovartisPharmaceuticalRegulationUSAVaccines

Global oncology market to hit $109 billion in 2020

Global oncology market to hit $109 billion in 2020

26-11-2014

Cancer, with a death toll exceeding that of AIDS (acquired immune deficiency syndrome), tuberculosis…

AvastinCelgene Corp.GlobalMarkets & MarketingMergers & AcquisitionsNovartisOncologyPharmaceuticalResearchRevlimidRoche

NICE updated guidance backs Novartis’ Glivec for GIST

26-11-2014

UK health costs watchdog the National Institute for Health and Care Excellence (NICE) has issued final…

GlivecNovartisOncologyPharmaceuticalPricingRegulationUK

Novartis' Signifor approved in EU for acromegaly patients

Novartis' Signifor approved in EU for acromegaly patients

25-11-2014

The European Commission has approved Swiss drug major Novartis’ Signifor (pasireotide) for patients…

NovartisPharmaceuticalRare diseasesRegulationSigniforSwitzerland

US FDA pushes back decision date for Novartis’ panobinostat

US FDA pushes back decision date for Novartis’ panobinostat

25-11-2014

The US Food and Drug Administration has extended its priority review period by up to three months for…

FarydakNovartisOncologypanobinostatPharmaceuticalRegulationUSA

Future bleak for Novartis’ panobinostat in relapsed/refractory multiple myeloma, says analyst

21-11-2014

The vote against the recommendation that the US Food and Drug Administration approves Novartis’ panobinostat…

daratumumabelotuzumabFarydakNovartisOncologypanobinostatPharmaceuticalRegulation

NICE seeks more information on Xolair to treat hives

19-11-2014

UK health costs watchdog the National Institute for Health and Care Excellence (NICE) is calling on Swiss…

DermatologicalsNovartisPharmaceuticalPricingRegulationUKXolair

Novartis’ LCZ696 reduces the risk of dying and hospitalizations

Novartis’ LCZ696 reduces the risk of dying and hospitalizations

18-11-2014

New data on Swiss drug major Novartis’ investigational medicine LCZ696, for patients with heart failure…

Cardio-vascularLCZ696NovartisPharmaceuticalResearchSwitzerland

Novartis announces positive results for secukinumab in psoriatic arthritis

Novartis announces positive results for secukinumab in psoriatic arthritis

17-11-2014

Swiss drug major Novartis has announced results from the pivotal Phase III FUTURE 1 and FUTURE 2 studies…

Anti-Arthritics/RheumaticsNovartisPharmaceuticalResearchsecukinumabSwitzerland

Scottish backing for Novartis’ Afinitor for kidney cancer patients

Scottish backing for Novartis’ Afinitor for kidney cancer patients

10-11-2014

The Scottish Medicines Consortium has issued a positive recommendation for Swiss pharma major Novartis’…

AfinitorClinical pharmacologyHealthHealth Medical PharmaNHSNovartisOncologyPharmaceuticalPricingRegulationUK

FDA advisory panel votes against approval of Novartis MM drug

07-11-2014

At a meeting yesterday, the US Food and Drug Administration's Oncologic Drugs Advisory Committee (ODAC)…

LBH589NovartisOncologypanobinostatPharmaceuticalRegulationUSA

Genmab transfers its ofatumumab collaboration from GSK to Novartis

Genmab transfers its ofatumumab collaboration from GSK to Novartis

03-11-2014

Danish biotech company Genmab has entered into an agreement with UK pharma major GlaxoSmithKline and…

DenmarkGenmabGSKNovartisOfatumumab InjectionOncologyPharmaceuticalResearch

India’s Cipla calls for revocation of Novartis’ Onbrez patents

01-11-2014

Indian drugmaker Cipla has asked the government to revoke five patents that Swiss pharma major Novartis…

CiplaIndiaMarkets & MarketingNovartisOnbrezPatentsPharmaceuticalRespiratory and PulmonaryUnibrez

Novartis’ strong third-qtr boosted by sale of Idenix stake

Novartis’ strong third-qtr boosted by sale of Idenix stake

28-10-2014

Swiss pharma major Novartis this morning reported that sales for the third quarter of 2014 rose 4% to…

AlconFinancialNovartisPharmaceuticalSandozSwitzerland

CSL buys Novartis’ influenza vaccines business for $275 million

CSL buys Novartis’ influenza vaccines business for $275 million

27-10-2014

Swiss pharma major Novartis has agreed to divest its influenza vaccines business to Australia’s CSL…

Anti-viralsbioCSLCSL LimitedFinancialMergers & AcquisitionsNovartisPharmaceuticalVaccines

Novartis' secukinumab achieves primary endpoints in Phase III studies for ankylosing spondylitis

Novartis' secukinumab achieves primary endpoints in Phase III studies for ankylosing spondylitis

23-10-2014

Swiss drug major Novartis says its investigational drug AIN457 (secukinumab) has achieved the primary…

Anti-Arthritics/RheumaticsNovartisPharmaceuticalResearchsecukinumabSwitzerland

FDA panel unanimously backs Novartis’ secukinumab for moderate-to-severe plaque psoriasis

FDA panel unanimously backs Novartis’ secukinumab for moderate-to-severe plaque psoriasis

21-10-2014

The Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) to the US Food and Drug Administration…

DermatologicalsNovartisPharmaceuticalRegulationsecukinumabUSA

US FDA panel votes to keep Chantix black box warning; staffers recommend secukinumab

US FDA panel votes to keep Chantix black box warning; staffers recommend secukinumab

17-10-2014

The US Food and Drug Administration's advisory panel has voted to keep a black box warning on US pharma…

ChantixNovartisPfizerPharmaceuticalRegulationsecukinumabUSA

NICE reverses guidance on Novartis’ Glivec for GIST

NICE reverses guidance on Novartis’ Glivec for GIST

17-10-2014

UK health costs watchdog the National Institute for Health and Care Excellence (NICE) has issued new…

GlivecNovartisOncologyPharmaceuticalPricingRegulationUK

Strong new data for Novartis’ investigational leukemia drug CTL019

16-10-2014

Swiss pharma giant Novartis and the US University of Pennsylvania's Perelman School of Medicine (Penn)…

CTL019NovartisOncologyPharmaceuticalResearch

Novartis is fined by Indian pricing authority over Voveran

Novartis is fined by Indian pricing authority over Voveran

14-10-2014

Swiss pharma major Novartis has received a penalty charge of 3 billion rupees from the Indian National…

AnalgesiadiclofenacIndiaLegalNovartisPharmaceutical

Novartis suspends commissioning of new Russian plant

13-10-2014

Swiss pharma major Novartis has decided to suspend the commissioning of its new Russian plant, which…

FinancialNovartisPharmaceuticalProductionRussia

1 to 25 of 357 results

Back to top